Skip to content

Trial Summary

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM.

Acronym:

DREAMM 3

ACTRN/NCT /ethics:

NCT04162210

Scientific title:

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Sponsor / Cooperative group:

GlaxoSmithKline

Trial & Patient Characteristics

Cancer TypeBlood
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-04-02
Anticipated End Date2024-11-21

Participating Hospitals

HospitalCalvary North Adelaide Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Wilfrid Jaksic
Recruitment StatusRecruiting